Human observational studies examining circulating METRNL levels have produced heterogeneous results, reflecting differences in study design, metabolic state, and assay methodology
Statistical measures, including risk ratios and confidence intervals, were used to assess the relative risks of GI complications associated with each medication
Belcaro G, Hosoi M, Pellegrini L, Appendino G, Ippolito E, Ricci A,
Triple agonist #retatrutide (GLP-1, GIP, Glucagon) achieved 22-24% weight loss at 48 weeks with a similar tolerability profile to #tirzepatide
Several dual GLP-1/GIP receptor agonists have been tested in phase 1 to phase 3 trials, including NNC0090-2746 (also known as RG7697), a fatty acylated version of a GLP-1/GIP co-agonist [16] and tirzepatide (also known as LY3298176) [17]
If you are prescribed glutathione, you will want to monitor your levels to ensure that it is having the desired effect (Guilford, 2012)